ReAlta’s lead candidate, pegtarazimod (RLS-0071), is a 15-amino-acid peptide designed to inhibit complement activation at C1 and to reduce myeloperoxidase activity and neutrophil extracellular trap formation. Pegtarazimod was derived from a mechanistic discovery of human astrovirus HAstV-1 and has shown a favorable tolerability profile across multiple clinical studies in healthy volunteers and patients with life-threatening inflammatory conditions. The company is developing pegtarazimod as a potential first-in-class therapy for Hypoxic Ischemic Encephalopathy (HIE) and has received FDA Orphan Drug and Fast Track designations as well as EMA Orphan Drug designation for HIE. The STAR trial (NCT05778188) is a two-stage, randomized, double-blind, placebo-controlled Phase 2 study currently enrolling newborns with moderate or severe HIE at 13 U.S. NICUs undergoing therapeutic hypothermia. ReAlta has positioned the program to deliver key clinical readouts and regulatory interactions following the recent financing. The company has raised more than $150 million to date and is headquartered in Norfolk, Va.

Total raised

$77M

Funding rounds

4

Latest round

Equity

Latest activity

Apr 2026